AC Immune SA (ACIU) Stock Rating Upgraded by Zacks Investment Research
AC Immune SA (NASDAQ:ACIU) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, July 5th. The firm currently has a $10.00 price target on the stock. Zacks Investment Research‘s target price indicates a potential upside of 49.25% from the company’s previous close.
According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “
Separately, Credit Suisse Group set a $18.00 target price on AC Immune SA and gave the company a “buy” rating in a research report on Wednesday, May 31st.
Shares of AC Immune SA (NASDAQ ACIU) remained flat at $6.70 during trading on Wednesday. 17,658 shares of the company’s stock traded hands. The stock’s market capitalization is $381.38 million. The stock has a 50-day moving average price of $8.53 and a 200-day moving average price of $10.19. AC Immune SA has a 1-year low of $6.66 and a 1-year high of $19.97.
AC Immune SA (NASDAQ:ACIU) last issued its quarterly earnings data on Thursday, May 11th. The company reported ($0.17) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.17). The firm had revenue of $1.99 million for the quarter, compared to analysts’ expectations of $3.43 million. On average, equities research analysts predict that AC Immune SA will post ($0.58) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/04/ac-immune-sa-aciu-lifted-to-buy-at-zacks-investment-research-updated-updated-updated.html.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cohen Lawrence B acquired a new position in shares of AC Immune SA during the second quarter valued at about $297,000. Monashee Investment Management LLC raised its position in shares of AC Immune SA by 74.7% in the first quarter. Monashee Investment Management LLC now owns 30,000 shares of the company’s stock valued at $311,000 after buying an additional 12,832 shares during the period. Victory Capital Management Inc. raised its position in shares of AC Immune SA by 78.4% in the first quarter. Victory Capital Management Inc. now owns 26,757 shares of the company’s stock valued at $277,000 after buying an additional 11,757 shares during the period. GSA Capital Partners LLP acquired a new position in shares of AC Immune SA during the fourth quarter valued at about $457,000. Finally, FMR LLC raised its position in shares of AC Immune SA by 13.4% in the fourth quarter. FMR LLC now owns 3,637,402 shares of the company’s stock valued at $46,344,000 after buying an additional 428,815 shares during the period. Institutional investors and hedge funds own 18.47% of the company’s stock.
About AC Immune SA
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related stocks with our FREE daily email newsletter.